Aims: To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer.
Materials And Methods: A phase II study.
Results: In total, 22 patients were treated with a combination of raltitrexed 3 mg/m2 every 3 weeks and mitomycin-C 7 mg/m2 every 6 weeks for up to 24 weeks. The study was closed early for safety reasons as there were three unexpected treatment-related deaths. The overall response rate was 20%, and a further 40% achieved stable disease. The median time to progression was 3.9 months and the median overall survival time was 11.6 months.
Conclusion: Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clon.2006.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma.
Front Med (Lausanne)
October 2024
Department of Radiotherapy, The Affiliated Chuzhou Hospital of Anhui Medical University, Chuzhou, China.
Objective: To evaluate the effectiveness and safety of concurrent chemoradiotherapy using Endostar continuous infusion for treating oesophageal squamous cell carcinoma (OSCC).
Method: A total of 62 patients with oesophageal carcinoma were divided into three groups: the Endostar continuous infusion group ( = 27), the Endostar intravenous drip group ( = 21) and the concurrent chemoradiotherapy group ( = 14). All patients underwent oesophageal radiotherapy (56-60 Gy) alongside concurrent chemotherapy (4 mg of raltitrexed +100 mg of oxaliplatin, two cycles).
Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial.
Nat Commun
October 2024
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Most patients with advanced hepatocellular carcinoma (HCC) ultimately experience tumor progression after first-line systemic therapies. Systemic therapy is generally recommended as second-line treatment for advanced HCC in the major guidelines. Combining apatinib with hepatic arterial infusion chemotherapy (HAIC) likely drives synergistic activity on advanced HCC with extrahepatic metastasis.
View Article and Find Full Text PDFEfficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.
J Evid Based Med
September 2024
Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Article Synopsis
- This study compares the effectiveness and safety of two treatment combinations for patients with refractory metastatic colorectal cancer: RS + fruquintinib versus RS + bevacizumab.
- Researchers used propensity score matching to ensure the two patient groups were balanced for fair comparison.
- Results showed that patients treated with RS + fruquintinib had longer progression-free survival and overall survival, with manageable side effects observed in both treatment groups.
Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens.
Eur J Med Res
September 2024
Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, No. 74, Linjiang Road, Yuzhong District, Chongqing Municipality, 400010, People's Republic of China.
Background: Portal vein tumor thrombosis (PVTT) commonly occurs in patients with primary liver cancer (PLC). Transarterial chemoembolization (TACE) is a treatment for patients with PLC and PVTT. Some studies have shown that combining TACE therapy with hepatic arterial infusion chemotherapy (HAIC) might improve the survival rate of PLC patients with PVTT.
View Article and Find Full Text PDFRaltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial.
Cancer Control
September 2024
Medical Oncology Department, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Objectives: Clinical studies have shown that bevacizumab plus chemotherapy significantly improves efficacy in metastatic colorectal cancer (mCRC). This prospective study aims to investigate the efficacy and safety of changing second-line treatment to raltitrexed-based chemotherapy regimens plus bevacizumab in mCRC patients who have failed the first-line fluorouracil-based chemotherapy regimen with or without bevacizumab/cetuximab.
Methods: This is a prospective, open-label, multicenter, phase II clinical study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!